V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10459636 | 10065256 | null | null | Curative (C) | 2022-03-17 | 2022-04-01 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | N | FEC | 101531292 |
| 10460308 | 10065261 | 1.82 | null | null | 2019-07-11 | 2019-07-11 | PCV | Y | null | OSIMERTINIB | 101674381 |
| 10460339 | 10065262 | 1.73 | 91.4 | null | 2020-06-16 | 2020-08-29 | Pemetrexed | 02 | null | LIPOSOMAL DAUNORUBICIN + LIPOSOMAL CYTARABINE (VYXEOS) | 101834345 |
| 10460666 | 10065264 | 1.63 | 64.4 | Neo-adjuvant (N) | 2021-02-11 | 2021-06-30 | Cisplatin + Pemetrexed | 02 | N | BENDAMUSTINE | 101298396 |
| 10461281 | 10065266 | 1.64 | 81.1 | Disease modification (D) | 2018-02-14 | 2019-03-18 | Cape+Cisplatin+Trastuzumab Main | 2 | N | BENDAMUSTINE + CYTARABINE + RITUXIMAB | 100530210 |
| 10461875 | 10065269 | 1.65 | 101.9 | null | 2016-09-02 | 2016-09-02 | Pentostatin | Y | null | PACLITAXEL + TRASTUZUMAB | 101721378 |
| 10462117 | 10065270 | 1.65 | 63.3 | null | 2021-09-13 | 2021-09-18 | Asciminib | 02 | null | DA | 101325522 |
| 10462633 | 10065273 | 1.71 | 70.4 | Adjuvant (A) | 2022-03-14 | 2022-03-20 | ECX | 02 | N | ANAGRELIDE | 100657905 |
| 10462918 | 10065275 | 1.7 | 71.3 | null | null | 2018-09-13 | Trial Unspecified | Y | null | CYCLOPHOSPHAMIDE + ETOPOSIDE | 100188063 |
| 10463139 | 10065277 | null | null | null | 2018-01-06 | 2018-01-10 | Trial Unspecified | 02 | N | TALIMOGENE LAHERPAREPVEC | 100821151 |
| 10463581 | 10065280 | 1.71 | 53.7 | null | 2018-07-27 | 2018-08-17 | Pemetrexed | 02 | N | IPILIMUMAB | 101189011 |
| 10463603 | 10065281 | 1.61 | 64 | null | 2019-04-03 | 2019-04-11 | Capecitabine + Mitomycin | 02 | null | CAPECITABINE + MITOMYCIN | 101362817 |
| 10463797 | 10065283 | null | null | Palliative (P) | 2017-05-10 | 2017-05-12 | Cyclophosphamide + Docetaxel | 02 | N | IPILIMUMAB | 100361329 |
| 10464201 | 10065284 | 0 | 66.3 | null | 2020-03-30 | 2020-03-30 | null | 02 | null | PEMETREXED | 100004424 |
| 10464465 | 10065285 | 0 | 61.5 | Palliative (P) | 2014-05-21 | 2014-06-29 | null | 02 | N | OBINUTUZUMAB + VENETOCLAX | 100103226 |
| 10464820 | 10065287 | 1.81 | 100 | Palliative (P) | 2019-05-03 | 2019-05-03 | MPT | 02 | N | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101095479 |
| 10464960 | 10065288 | 1.8 | 103 | Curative (C) | 2020-07-17 | 2021-02-22 | LEAM | 02 | N | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 101572022 |
| 10465351 | 10065290 | 0 | 81.5 | null | 2020-09-03 | 2020-10-01 | Letrozole + Palbociclib | 02 | null | CAV | 100437259 |
| 10465398 | 10065291 | 1.64 | 92.1 | Palliative (P) | 2018-11-23 | 2018-11-30 | ABEMACICLIB + FULVESTRANT | null | N | SORAFENIB | 101150734 |
| 10465735 | 10065292 | 1.88 | 57.8 | null | 2021-01-17 | 2021-02-27 | BENDAMUSTINE | 02 | null | ERIBULIN | 101320526 |
| 10465757 | 10065293 | 1.93 | 80.1 | null | 2020-03-18 | 2020-04-16 | null | 02 | null | PEMETREXED | 101283390 |
| 10465806 | 10065294 | 1.57 | 57.5 | Curative (C) | 2019-10-29 | 2019-10-31 | STAMPEDE TRIAL | 02 | N | ISATUXIMAB + POMALIDOMIDE | 100242858 |
| 10465839 | 10065295 | 1.68 | 80.6 | Palliative (P) | 2020-04-24 | 2020-05-31 | null | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100496246 |
| 10465984 | 10065296 | 1.64 | 90 | null | 2019-05-24 | 2019-05-24 | Dasatinib | null | null | GEMCITABINE + NAB-PACLITAXEL | 100719306 |
| 10466000 | 10065297 | 1.7 | 75 | null | 2018-08-04 | 2020-07-25 | Doxorubicin chemoembolisation | 02 | null | PEMETREXED | 101755483 |
| 10466066 | 10065298 | 1.65 | 78 | Palliative (P) | 2018-03-04 | 2018-03-08 | TALIMOGENE LAHERPAREPVEC | 02 | null | DASATINIB | 101073213 |
| 10466178 | 10065299 | null | null | Adjuvant (A) | 2017-03-25 | 2018-04-09 | Pemetrexed | 02 | N | DOXORUBICIN + OLARATUMAB | 101557693 |
| 10466233 | 10065300 | 0 | 79.6 | Palliative (P) | 2021-10-03 | 2021-10-15 | Thalidomide 200mg | 02 | N | CTD | 101386523 |
| 10466432 | 10065301 | 1.52 | 84.7 | null | 2016-12-24 | 2017-01-26 | Sunitinib | 02 | null | DURVALUMAB | 101256506 |
| 10466480 | 10065302 | 1.58 | 71.6 | Curative (C) | 2017-07-10 | 2017-07-12 | null | 02 | N | OSIMERTINIB | 101199601 |
| 10466578 | 10065303 | 1.84 | 83 | Palliative (P) | 2018-06-28 | 2018-06-28 | Bevacizumab 7.5mg/kg | 02 | N | FLUOROURACIL + MITOMYCIN | 100674194 |
| 10466858 | 10065305 | 0 | 72 | Palliative (P) | 2017-03-28 | 2017-04-01 | Doxorubin 50mg/m2 | 02 | N | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 101035522 |
| 10467132 | 10065306 | 1.71 | 52 | 03 | 2019-08-30 | 2019-09-04 | Durvalumab | 02 | N | BELANTAMAB MAFODOTIN | 100879248 |
| 10467140 | 10065307 | 1.69 | 0 | null | 2017-10-15 | 2017-11-12 | MELPHALAN + THALIDOMIDE | 02 | null | BORTEZOMIB + MELPHALAN | 100096909 |
| 10467175 | 10065309 | 1.75 | 86.7 | Curative (C) | 2018-11-10 | 2019-06-19 | null | 02 | null | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | 101641637 |
| 10467214 | 10065310 | 1.82 | 66.7 | null | 2021-10-22 | 2021-10-22 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 02 | null | DURVALUMAB | 101200479 |
| 10467904 | 10065314 | 1.85 | 56.4 | Curative (C) | 2019-07-21 | 2019-07-21 | Liposomal Doxorubicin 40mg/m2 | 02 | N | PANOBINOSTAT | 101058072 |
| 10468004 | 10065315 | 1.64 | 90.7 | Palliative (P) | 2022-01-08 | 2022-01-23 | null | 02 | N | CLADRIBINE | 101096281 |
| 10468234 | 10065316 | null | null | null | 2020-01-28 | 2020-02-01 | CAPECITABINE + CARBOPLATIN + Trastuzumab | 02 | null | CETUXIMAB + ENCORAFENIB | 100891207 |
| 10468465 | 10065318 | 1.75 | 60.4 | null | 2019-02-27 | 2019-09-24 | Cladribine (subcut) 5 days | 02 | null | CARFILZOMIB | 101175957 |
| 10468511 | 10065319 | 1.69 | 0 | null | 2017-09-18 | 2017-09-18 | Cyclophosphamide + Docetaxel | N | null | GEMCARBO | 101838528 |
| 10468761 | 10065320 | 1.53 | 73 | null | 2018-08-09 | 2018-08-28 | MYELOMA XI TRIAL | 02 | null | PEG INTERFERON | 100421318 |
| 10468857 | 10065321 | 1.67 | null | null | 2020-01-09 | 2020-01-15 | null | 01 | null | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 101815249 |
| 10468917 | 10065322 | 1.73 | 56 | null | 2018-11-25 | 2018-12-03 | Cetuximab + Radiotherapy Maint | 02 | null | PETREA TRIAL | 101316497 |
| 10468967 | 10065323 | 1.73 | 85.8 | 03 | 2019-03-19 | 2019-03-25 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | N | CARBOPLATIN + PACLITAXEL + PEMBROLIZUMAB | 100902118 |
| 10469564 | 10065324 | 1.52 | 69.9 | Curative (C) | 2020-11-02 | 2020-11-24 | Mitomycin Intravesical | 02 | N | BLEOMYCIN | 100168725 |
| 10469694 | 10065326 | 1.84 | 0 | Curative (C) | 2018-07-30 | 2018-08-02 | DOCETAXEL + FLUOROURACIL + OXALIPLATIN | 02 | N | NAB-PACLITAXEL | 101595280 |
| 10469699 | 10065327 | null | null | Palliative (P) | 2021-01-06 | 2021-02-03 | Ripretinib | 02 | N | MERCAPTOPURINE | 101325936 |
| 10469800 | 10065328 | 1.81 | 72.3 | 03 | 2018-01-03 | 2019-10-14 | FCR | 02 | N | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 100844177 |
| 10470026 | 10065329 | 1.85 | 45.7 | Palliative (P) | 2020-08-18 | 2020-08-18 | DHAP - R | 02 | N | BEVACIZUMAB | 100238493 |